These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 11382726)

  • 41. Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment.
    Brown DL
    Heart; 2003 May; 89(5):535-7. PubMed ID: 12695459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up.
    Roffi M; Moliterno DJ; Meier B; Powers ER; Grines CL; DiBattiste PM; Herrmann HC; Bertrand M; Harris KE; Demopoulos LA; Topol EJ;
    Circulation; 2002 Jun; 105(23):2730-6. PubMed ID: 12057986
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
    Ibbotson T; McGavin JK; Goa KL
    Drugs; 2003; 63(11):1121-63. PubMed ID: 12749745
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
    Gibson CM; Moynihan JL; Al-Mousa EN; Campsey M; Gandhi R; Murphy S; Mattson S; Ryan KA; Mesley R; Swanson J; Arshad MN; Marble SJ
    J Thromb Thrombolysis; 1999 Jun; 7(3):287-302. PubMed ID: 10375390
    [No Abstract]   [Full Text] [Related]  

  • 46. Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?).
    Kalyanasundaram A; Blankenship JC; Berger P; Herrmann H; McClure R; Moliterno D
    Catheter Cardiovasc Interv; 2007 Apr; 69(5):623-9. PubMed ID: 17192960
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An audit of the use and complications of glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention against national UK standards.
    Sheikh A; Baig K
    Cardiovasc Revasc Med; 2006; 7(4):237-9. PubMed ID: 17174871
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes.
    Jennings LK
    Expert Opin Drug Metab Toxicol; 2005 Dec; 1(4):727-37. PubMed ID: 16863436
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glycoprotein IIb/IIIa inhibitors during rescue percutaneous coronary intervention in acute myocardial infarction.
    Gruberg L; Suleiman M; Kapeliovich M; Hammerman H; Grenadier E; Boulus M; Amikam S; Markiewicz W; Beyar R
    J Invasive Cardiol; 2006 Feb; 18(2):59-62. PubMed ID: 16446517
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
    Tcheng JE
    Am J Cardiol; 1996 Aug; 78(3A):35-40. PubMed ID: 8751845
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention.
    Fahdi IE; Saucedo JF; Hennebry T; Ghani M; Sadanandan S; Garza-Arreola L
    Am J Cardiol; 2004 Feb; 93(4):453-5. PubMed ID: 14969621
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
    Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.
    Peter K; Kohler B; Straub A; Ruef J; Moser M; Nordt T; Olschewski M; Ohman ME; Kübler W; Bode C
    Circulation; 2000 Sep; 102(13):1490-6. PubMed ID: 11004138
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy.
    Wheeler GL; Braden GA; Steinhubl SR; Kereiakes DJ; Kottke-Marchant K; Michelson AD; Furman MI; Mueller MN; Moliterno DJ; Sane DC
    Am Heart J; 2002 Apr; 143(4):602-11. PubMed ID: 11923796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Ernst NM; Suryapranata H; Miedema K; Slingerland RJ; Ottervanger JP; Hoorntje JC; Gosselink AT; Dambrink JH; de Boer MJ; Zijlstra F; van 't Hof AW
    J Am Coll Cardiol; 2004 Sep; 44(6):1187-93. PubMed ID: 15364318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
    Kralisz P; Dobrzycki S; Nowak K; Kochman W; Gajewska-Bachórzewska H; Gugała K; Mezyński G; Prokopczuk P; Zuk J; Korecki J; Poniatowski B; Musiał W
    Kardiol Pol; 2004 May; 60(5):459-67. PubMed ID: 15247961
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.
    Deibele AJ; Jennings LK; Tcheng JE; Neva C; Earhart AD; Gibson CM
    Circulation; 2010 Feb; 121(6):784-91. PubMed ID: 20124127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.